Vivoryon Therapeutics N.V. Stock
Stocks
VVY
NL00150002Q7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Amsterdam
11:55:00 2026-11-20 EST
|
5-day change | 1st Jan Change | ||
| 0.6300 EUR | -1.56% |
|
-17.97% | -55.63% |
| 08-06 | Vivoryon Therapeutics N.V., H1 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 18.66M 20.48M 17.19M 15.64M 29.34M 1.9B 30.83M 209M 83.16M 1.04B 76.86M 75.24M 3.25B | P/E 2026 * |
-1.66x | P/E 2027 * | -1.7x |
|---|---|---|---|---|---|
| Enterprise Value | 22.98M 25.23M 21.17M 19.26M 36.13M 2.34B 37.97M 258M 102M 1.28B 94.65M 92.66M 4B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
95.15% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext AmsterdamEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| VVY | Real-time | |
| 05Y | Real-time | ||
| VVY | Real-time | ||
| 05Y | Delayed | ||
| VVYN | End-of-day quote | ||
| 0R3M | Real-time | ||
| 05Y | Real-time | ||
| 05Y | Delayed |
Last Transcript: Vivoryon Therapeutics N.V.
| 1 day | -1.56% | ||
| 1 week | -17.97% | ||
| Current month | -21.45% | ||
| 1 month | -31.07% | ||
| 3 months | -44.00% | ||
| 6 months | -49.40% | ||
| Current year | -55.63% |
| 1 week | 0.6 | 0.77 | |
| 1 month | 0.52 | 0.91 | |
| Current year | 0.52 | 1.65 | |
| 1 year | 0.52 | 1.65 | |
| 3 years | 0.41 | 9.93 | |
| 5 years | 0.41 | 20.64 | |
| 10 years | 0.41 | 23.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 66 | 2023-08-13 |
Marcus Irsfeld
DFI | Director of Finance/CFO | - | 2025-11-30 |
Julia Neugebauer
COO | Chief Operating Officer | - | 2025-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 2006-12-31 | |
Frank Weber
BRD | Director/Board Member | 66 | 2023-09-14 |
| Director/Board Member | 58 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/23/25 | Free | Chief Operating Officer | 20,000 | 0.0767% | ||
| 10/23/25 | Buy | Chief Executive Officer | 135,000 | 0.5179% | ||
| 10/23/25 | Free | 20,000 | 0.0767% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.56% | -17.97% | -60.62% | -92.33% | 20.48M | ||
| -2.49% | -3.76% | +50.31% | +62.10% | 63.66B | ||
| -0.63% | -2.91% | +6.20% | +89.22% | 58.56B | ||
| -2.37% | -2.22% | +22.87% | +82.31% | 54.19B | ||
| -2.19% | -6.15% | +11.92% | +108.08% | 44.66B | ||
| -1.89% | -7.28% | +13.22% | +19.74% | 40.51B | ||
| -0.93% | -0.47% | +19.73% | +43.75% | 36.27B | ||
| +1.11% | -6.44% | +130.68% | +641.83% | 34.89B | ||
| -0.80% | +0.61% | +77.26% | +56.26% | 32.26B | ||
| -2.17% | +16.65% | -29.21% | +474.05% | 31.01B | ||
| Average | -1.39% | -2.89% | +24.24% | +148.50% | 40B | |
| Weighted average by Cap. | -1.48% | -1.85% | +32.15% | +150.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -10.4M -11.42M -9.58M -8.72M -16.35M -1.06B -17.19M -117M -46.36M -578M -42.84M -41.94M -1.81B | -10.4M -11.42M -9.58M -8.72M -16.35M -1.06B -17.19M -117M -46.36M -578M -42.84M -41.94M -1.81B |
| Net Debt | 4.32M 4.74M 3.98M 3.62M 6.79M 439M 7.14M 48.45M 19.26M 240M 17.8M 17.42M 753M | 13.03M 14.31M 12.01M 10.92M 20.49M 1.32B 21.53M 146M 58.08M 724M 53.68M 52.54M 2.27B |
Employees
13
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-20 | €0.6300 | -1.56% | 11,856 |
| 26-11-19 | €0.6400 | -3.32% | 12,354 |
| 26-11-18 | €0.6620 | -6.76% | 93,521 |
| 26-11-17 | €0.7100 | -2.74% | 14,501 |
| 26-11-16 | €0.7300 | -4.95% | 32,985 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6300EUR
Average target price
6.850EUR
Spread / Average Target
+987.30%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VVY Stock
Select your edition
All financial news and data tailored to specific country editions
















